The production of hybrid anthracycline antibiotics by biosynthetic conversion of natural and semisynthetic anthracyclinones using antibioticblocked mutants of anthracycline producers is now saccharide would be also an expected bioconversion product. However, we were unable to obtain BCM-B in the microbial conversion with strain KE-303. In this paper we describe production of BCM-B by the selected biosynthetic glycosidation of 0-RMN using a new ACM-nonproducing mutant strain 2HK-0134 which was derived from a mutant strain 7N-367 that produce large amounts of ACM-B.4) BCM-Bthus obtained exhibited higher antitumor activity in vivo against leukemic LI210 cell culture than BCM-A.The chemical structure of BCM-B which was finally established is shown in Fig. 1 .
Microbial conversion with strain 2HK-0134 was carried out using a 3-liter jar fermenter containing The conversion broth from two fermentation runs was collected and centrifuged. The pigmented product was extracted from the mycelial cake with a total of 3 liters ofacetone. The solvent extract was evaporated and extracted with 1 liter of CHC13.
After evaporation of the CHC13layer, the pigmented residue was dissolved in about 20ml of CHC13-MeOH(1:2) mixture, and put on a top of a Sephadex LH-20 column (20 x 400mm), which was eluted with the same solvent mixture. Fractions were monitored by TLC on a Silica gel plate 60 F254 using a solvent ofCHC13 -MeOH(15 : 1) and those containing the glycosidated products were pooled and were found to be L-rhodosamine, 2-deoxy-L-fucose and cinerulose B.
Its sugar componentswere same as those ofACM-B based on a comparative TLC sugar analysis. Methanolysis of BCM-Baccording to the method The spectra were measured in CDC13at 100MHz
using TMSas an internal reference. The antitumor activity of BCM-B is shown in Table 3 . BCM-Bwas very active as was BCM-A against leukemic LI210 cell culture when the bioactivities were assayed as previously described.8) IC50 value (fig/ml) against the cell growth was 0.005 which was 40 times more active than doxorubicin (0.02). The IC50 ratio of RNA synthesis to DNA synthesis was 2.2 and also lower than that of doxorubicin (2.5) and BCA-A (3.8). Thus, BCM-B exhibited a greater effect on the inhibition of DNA synthesis than these agents. Antitumor activity in vivo of BCM-Bagainst L1210 in mice was 240% (T/C%) with an optimum dose of 1.25mg/kg/day on day 1 to 10 under ip-ip treatment. BCM-Bwas superior to BCM-Ain this model.
